Viridian Therapeutics Inc VRDN
News
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Viridian Therapeutics Says FDA Approves Lumvoa to Treat Thyroid Eye Disease
Viridian Shares Fall After Competing Amgen Eye Drug Performs Well
Viridian Therapeutics in Royalty Financing Deal With DRI Healthcare for Up to $300 Million
